Assessment of minimal residual disease in acute myeloid leukemia.
about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaDeep Response in Multiple Myeloma: A Critical ReviewEradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Minimal residual disease in acute myeloid leukaemiaDetection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Recent advancements of flow cytometry: new applications in hematology and oncology.Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaNew considerations in the design of clinical trials for the treatment of acute leukemia.Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationSynergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.A critical review of which children with acute myeloid leukaemia need stem cell procedures.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot.The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.[Acute myeloid leukemia. Genetic diagnostics and molecular therapy].Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.Universal monitoring of minimal residual disease in acute myeloid leukemia.Relapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene
P2860
Q26744111-B7D89E6C-F00E-49A1-8868-2B3D7ED125FCQ26771228-339BBEE0-F620-43D2-9910-D80E35A9033DQ33794311-6F6030FC-5450-4A3D-BF4B-886A161527ECQ33877213-E3E3294C-198E-4178-957C-277321DAB957Q34179265-1AB289F7-2D2B-44CD-9913-DBE8549BD628Q34364350-2469277F-26F0-464B-9FAF-1D9D942C9628Q35059549-4B3599CC-803C-4AEF-B023-EE0A44F06F19Q35835657-3F4DD4D3-9AB4-4F86-A4DB-9BBE8722A426Q35849281-21C61C73-D4F3-422D-A149-679BE7CA4C32Q36290737-3C923543-240F-498E-8EB3-73CA8A1686AEQ36641721-4BCC8F6F-C805-4F7A-897C-9DB21ADC7A95Q36920398-7385613E-991F-4EC9-AD21-79CCEE500ADFQ37397791-A3236E37-7DE6-4CF2-BC41-D63A61DABCF9Q37850824-2D69A7B7-C3E2-4AF9-A5E2-30BA2C4988E1Q38022075-D692A32B-B192-4226-9EEB-A9C65B2B12EBQ38205864-133A3890-2111-462D-A8C2-470BBB26479DQ38212956-CDD1D9D7-B935-46F0-92E3-C19BBF04AE23Q38240563-FA04D364-CB95-4E05-94AB-8C0C2F6E9E66Q38261856-ADD4C098-042C-4711-B7C0-5B4E43F26EC0Q38481997-B460C236-FB79-4F07-A5DF-132140F61E8CQ39552773-10F87623-A90F-4B97-B6E6-AC9860AADF0BQ41553306-D3F7F2CD-7F15-466C-BA35-793C78C0F1A8Q42930435-75A2A35D-7AF0-405B-92B0-AB47A52B3C55Q44222759-A2AEA223-E8A9-4051-85F4-6E11F38A0BC3Q46651101-5570C739-F277-4E58-AE28-F0A786436511Q47745405-6FF6156F-DC8A-4E1A-AA77-8BF1115E62A4Q53610644-64BC3804-ACB9-489A-8FF3-154DAD69E762Q54475024-CC065278-C08C-4A91-80E5-F2DF47A52D74Q55333539-2C604D41-A0D5-4260-8568-8F2E8633168DQ59194210-5EFBF96E-C25A-4489-B401-71E909775DF1
P2860
Assessment of minimal residual disease in acute myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Assessment of minimal residual disease in acute myeloid leukemia.
@en
Assessment of minimal residual disease in acute myeloid leukemia.
@nl
type
label
Assessment of minimal residual disease in acute myeloid leukemia.
@en
Assessment of minimal residual disease in acute myeloid leukemia.
@nl
prefLabel
Assessment of minimal residual disease in acute myeloid leukemia.
@en
Assessment of minimal residual disease in acute myeloid leukemia.
@nl
P1476
Assessment of minimal residual disease in acute myeloid leukemia.
@en
P2093
David Grimwade
P304
P356
10.1097/CCO.0B013E32833ED831
P577
2010-11-01T00:00:00Z